haematological and vascular complications affecting the liver dominique-charles valla hôpital...
TRANSCRIPT
![Page 1: Haematological and vascular complications affecting the liver Dominique-Charles Valla Hôpital Beaujon, Clichy, France BSG Postgraduate Course Birmingham](https://reader035.vdocument.in/reader035/viewer/2022062516/56649ddb5503460f94ad1e8a/html5/thumbnails/1.jpg)
Haematological and vascular complications affecting the liver
Dominique-Charles Valla
Hôpital Beaujon, Clichy, France
BSG Postgraduate CourseBirmingham 2006
![Page 2: Haematological and vascular complications affecting the liver Dominique-Charles Valla Hôpital Beaujon, Clichy, France BSG Postgraduate Course Birmingham](https://reader035.vdocument.in/reader035/viewer/2022062516/56649ddb5503460f94ad1e8a/html5/thumbnails/2.jpg)
Blood disorders affecting the liver
• Lymphoproliferative or myeloproliferative diseases
• Activated Macrophages
• Lymphoproliferative diseases
• Prothombotic disorders
Infiltration
InfiltrationCytokine release
Light chain deposition
Thrombosis
![Page 3: Haematological and vascular complications affecting the liver Dominique-Charles Valla Hôpital Beaujon, Clichy, France BSG Postgraduate Course Birmingham](https://reader035.vdocument.in/reader035/viewer/2022062516/56649ddb5503460f94ad1e8a/html5/thumbnails/3.jpg)
Prothrombotic Disorders
Involvement of hepatic vessels
• Portal venous thrombosis large- or small-sized veins
• Hepatic venous thrombosis large- or small-sized veins
• Any combination thereof
![Page 4: Haematological and vascular complications affecting the liver Dominique-Charles Valla Hôpital Beaujon, Clichy, France BSG Postgraduate Course Birmingham](https://reader035.vdocument.in/reader035/viewer/2022062516/56649ddb5503460f94ad1e8a/html5/thumbnails/4.jpg)
Secondary architectural changes
• portal• central• sinusoidal
• macronodules • micronodules
Vascular obstruction
Sinusoidal dilatation
• central• random
AtrophyHypertrophy
Fibrosis
![Page 5: Haematological and vascular complications affecting the liver Dominique-Charles Valla Hôpital Beaujon, Clichy, France BSG Postgraduate Course Birmingham](https://reader035.vdocument.in/reader035/viewer/2022062516/56649ddb5503460f94ad1e8a/html5/thumbnails/5.jpg)
Prothrombotic disorders affecting hepatic vessels
• Extrahepatic portal vein thrombosisPylephlebitis and Portal cavernoma
• Hepatic vein/IVC thrombosisBudd-Chiari syndrome
• Intrahepatic vascular obstructionHepatic veins or Portal veins
• Non-cirrhotic architectural changes
Portal hypertension or Abnormal liver tests
![Page 6: Haematological and vascular complications affecting the liver Dominique-Charles Valla Hôpital Beaujon, Clichy, France BSG Postgraduate Course Birmingham](https://reader035.vdocument.in/reader035/viewer/2022062516/56649ddb5503460f94ad1e8a/html5/thumbnails/6.jpg)
Prothrombotic Disorders in BCS or PVT
Myeloproliferative diseases %
Hereditary thrombophilias %
Antiphospholipid syndrome %
PNH %
60 30
35 35
15 15
5 0
Janssen, Blood 2000. Deltenre, Gut, 2001. Primignani, Hepatology 2005
BCS PVT
![Page 7: Haematological and vascular complications affecting the liver Dominique-Charles Valla Hôpital Beaujon, Clichy, France BSG Postgraduate Course Birmingham](https://reader035.vdocument.in/reader035/viewer/2022062516/56649ddb5503460f94ad1e8a/html5/thumbnails/7.jpg)
• Healthy male patient, 39 year-old.Enlarged spleen (6 cm) at routine examination
• AST/ALT Normal WBC 9 000/fL GGT & ALP 1.8xULN Platelets 250 000/fL Prothrombin 72% RBC4.2 106/fLFactor V 70% Hematocrit 39%
• No cause for chronic liver disease
• CT / US : Portal cavernoma. • Grade III esophageal varices with red signs• Needle biopsy: Normal liver
Case history
![Page 8: Haematological and vascular complications affecting the liver Dominique-Charles Valla Hôpital Beaujon, Clichy, France BSG Postgraduate Course Birmingham](https://reader035.vdocument.in/reader035/viewer/2022062516/56649ddb5503460f94ad1e8a/html5/thumbnails/8.jpg)
WBC 9 000/fLPlatelets 250 000/fLHematocrit 39%Prothrombin 72%Factor V 70%
Antithrombin N > 75% 70%Protein C N > 65% 55%Protein S N > 65% 62%Factor V Leiden AbsentFactor II mutation PresentAPL Ab/LA Absent
![Page 9: Haematological and vascular complications affecting the liver Dominique-Charles Valla Hôpital Beaujon, Clichy, France BSG Postgraduate Course Birmingham](https://reader035.vdocument.in/reader035/viewer/2022062516/56649ddb5503460f94ad1e8a/html5/thumbnails/9.jpg)
How many causal factors have been fully identified ?
![Page 10: Haematological and vascular complications affecting the liver Dominique-Charles Valla Hôpital Beaujon, Clichy, France BSG Postgraduate Course Birmingham](https://reader035.vdocument.in/reader035/viewer/2022062516/56649ddb5503460f94ad1e8a/html5/thumbnails/10.jpg)
WBC 9 000/fLPlatelets 250 000/fLHematocrit 39%Prothrombin 72%Factor V 70%
Antithrombin N > 75% 70%Protein C N > 65% 55%Protein S N > 65% 62%Factor V Leiden AbsentFactor II mutation PresentAPL Ab/LA Absent
![Page 11: Haematological and vascular complications affecting the liver Dominique-Charles Valla Hôpital Beaujon, Clichy, France BSG Postgraduate Course Birmingham](https://reader035.vdocument.in/reader035/viewer/2022062516/56649ddb5503460f94ad1e8a/html5/thumbnails/11.jpg)
123
• F II gene mutation
• X
How many causal factors have been fully identified ?
![Page 12: Haematological and vascular complications affecting the liver Dominique-Charles Valla Hôpital Beaujon, Clichy, France BSG Postgraduate Course Birmingham](https://reader035.vdocument.in/reader035/viewer/2022062516/56649ddb5503460f94ad1e8a/html5/thumbnails/12.jpg)
WBCC 9 000/fLPlatelets 250 000/fLHematocrit 39%Prothrombin 72%Factor V 70%
Antithrombin N > 75% 70%Protein C N > 65% 55%Protein S N > 65% 62%Factor V Leiden AbsentFactor II mutation PresentAPL Ab/LA Absent
![Page 13: Haematological and vascular complications affecting the liver Dominique-Charles Valla Hôpital Beaujon, Clichy, France BSG Postgraduate Course Birmingham](https://reader035.vdocument.in/reader035/viewer/2022062516/56649ddb5503460f94ad1e8a/html5/thumbnails/13.jpg)
PVT - Coagulation inhibitors
Fisher. Gut 2000; 46:534
![Page 14: Haematological and vascular complications affecting the liver Dominique-Charles Valla Hôpital Beaujon, Clichy, France BSG Postgraduate Course Birmingham](https://reader035.vdocument.in/reader035/viewer/2022062516/56649ddb5503460f94ad1e8a/html5/thumbnails/14.jpg)
WBCC 9 000/fLPlatelets 250 000/fLHematocrit 39%Prothrombin 72%Factor V 70%
Antithrombin N > 75% 70%Protein C N > 65% 55%Protein S N > 65% 62%Factor V Leiden AbsentFactor II mutation PresentAPL Ab/LA Absent
![Page 15: Haematological and vascular complications affecting the liver Dominique-Charles Valla Hôpital Beaujon, Clichy, France BSG Postgraduate Course Birmingham](https://reader035.vdocument.in/reader035/viewer/2022062516/56649ddb5503460f94ad1e8a/html5/thumbnails/15.jpg)
Combination of prothrombotic disorders
At least 2 disorders (%) 25-35% 10-20%
BCS PVT
Denninger. Hepatology 2000. Janssen Blood 2000. Primignani Hepatology 2005
Myeloproliferative disease in 20-60% of patients with hereditary thrombophilias
![Page 16: Haematological and vascular complications affecting the liver Dominique-Charles Valla Hôpital Beaujon, Clichy, France BSG Postgraduate Course Birmingham](https://reader035.vdocument.in/reader035/viewer/2022062516/56649ddb5503460f94ad1e8a/html5/thumbnails/16.jpg)
WBCC 9 000/fLPlatelets 250 000/fLHematocrit 39%Prothrombin 72%Factor V 70%
Antithrombin N > 75% 70%Protein C N > 65% 55%Protein S N > 65% 62%Factor V Leiden AbsentFactor II mutation PresentAPL Ab/LA Absent
![Page 17: Haematological and vascular complications affecting the liver Dominique-Charles Valla Hôpital Beaujon, Clichy, France BSG Postgraduate Course Birmingham](https://reader035.vdocument.in/reader035/viewer/2022062516/56649ddb5503460f94ad1e8a/html5/thumbnails/17.jpg)
BCS or PVTFeatures of Myeloproliferative Disease
PPV
100%
Chait et al. Br J Haematol 2005
Δ Spleen > 5 cm
Platelets > 200 000/fL
![Page 18: Haematological and vascular complications affecting the liver Dominique-Charles Valla Hôpital Beaujon, Clichy, France BSG Postgraduate Course Birmingham](https://reader035.vdocument.in/reader035/viewer/2022062516/56649ddb5503460f94ad1e8a/html5/thumbnails/18.jpg)
Myeloproliferative diseases
• Classical criteria (PVSG) % 10 0• Endogenous erythroid colonies % 60 30• Bone marrow biopsy % 60 30• V617F JAK2 mutation % 60 30
Diagnostic criteria BCS PVT
James Nature 2005. Kralovics NEJM 2005. Baxter Lancet 2005. Levine Cancer Cell 2005.
Patel RK et al. ASH Dec 2005. Fabris FH et al. EASL 2006
![Page 19: Haematological and vascular complications affecting the liver Dominique-Charles Valla Hôpital Beaujon, Clichy, France BSG Postgraduate Course Birmingham](https://reader035.vdocument.in/reader035/viewer/2022062516/56649ddb5503460f94ad1e8a/html5/thumbnails/19.jpg)
• F II gene mutation• Myeloproliferative disease
• Portal vein thrombosis• Large oesophageal varices with
red signs
![Page 20: Haematological and vascular complications affecting the liver Dominique-Charles Valla Hôpital Beaujon, Clichy, France BSG Postgraduate Course Birmingham](https://reader035.vdocument.in/reader035/viewer/2022062516/56649ddb5503460f94ad1e8a/html5/thumbnails/20.jpg)
Would you recommend permanent anticoagulation ?
YES - NO
![Page 21: Haematological and vascular complications affecting the liver Dominique-Charles Valla Hôpital Beaujon, Clichy, France BSG Postgraduate Course Birmingham](https://reader035.vdocument.in/reader035/viewer/2022062516/56649ddb5503460f94ad1e8a/html5/thumbnails/21.jpg)
Disease-specific Antithrombotic Therapies
• Myeloproliferative diseases Hydroxyurea Low dose aspirin Anagrelide
• Other acquired or inherited conditions Little or no data
Cortelazzo NEJM 1995. Landolfi NEJM 2004. Eliott Br J Haematol 2004. Crother Thromb Res 2004. Harrisson NEJM 2005
Data still unclear for venous thromboses
![Page 22: Haematological and vascular complications affecting the liver Dominique-Charles Valla Hôpital Beaujon, Clichy, France BSG Postgraduate Course Birmingham](https://reader035.vdocument.in/reader035/viewer/2022062516/56649ddb5503460f94ad1e8a/html5/thumbnails/22.jpg)
Chronic Portal Vein Thrombosis
Condat et al. Gastroenterology 2001; 120:490
Thrombosis
6.0
yesno yesnoAnticoagulation Anticoagulation
1.2
Bleeding
7
17
per
100
pat
ien
tsp
er y
ear
p = 0.015
p = 0.212
![Page 23: Haematological and vascular complications affecting the liver Dominique-Charles Valla Hôpital Beaujon, Clichy, France BSG Postgraduate Course Birmingham](https://reader035.vdocument.in/reader035/viewer/2022062516/56649ddb5503460f94ad1e8a/html5/thumbnails/23.jpg)
Chronic PVT – GI Bleeding
Condat et al. Gastroenterology 2001;120:490-497
1724
Moderate/large-sized varices
yesnoProphylaxis
per
100
pat
ien
tsp
er y
ear
![Page 24: Haematological and vascular complications affecting the liver Dominique-Charles Valla Hôpital Beaujon, Clichy, France BSG Postgraduate Course Birmingham](https://reader035.vdocument.in/reader035/viewer/2022062516/56649ddb5503460f94ad1e8a/html5/thumbnails/24.jpg)
Orr et al. Hepatology 2005; 42: 212A (AASLD San Francisco 2005)
Chronic portomesenteric venous thrombosis
Hazard Ratio for Death
Beta-blockersyesno
0.28
1.00p=0.030
yesnoWarfarine
0.10
1.00p=0.038
![Page 25: Haematological and vascular complications affecting the liver Dominique-Charles Valla Hôpital Beaujon, Clichy, France BSG Postgraduate Course Birmingham](https://reader035.vdocument.in/reader035/viewer/2022062516/56649ddb5503460f94ad1e8a/html5/thumbnails/25.jpg)
Recanalisation
83 %
Anticoagulation (alone, n = 27)
Condat. Hepatology 2000
Thrombolysis (in situ, n = 20)
75 %
Acute Portal Vein Thrombosis
Holliingshead. J Vasc Interv Radiol 2005
![Page 26: Haematological and vascular complications affecting the liver Dominique-Charles Valla Hôpital Beaujon, Clichy, France BSG Postgraduate Course Birmingham](https://reader035.vdocument.in/reader035/viewer/2022062516/56649ddb5503460f94ad1e8a/html5/thumbnails/26.jpg)
Acute Portal Vein Thrombosis
0
100Major Bleeding
60%
Thrombolysis (in situ, n = 20)
5%
Anticoagulation (alone, n = 27)
Condat. Hepatology 2000
Holliingshead. J Vasc Interv Radiol 2005
%
![Page 27: Haematological and vascular complications affecting the liver Dominique-Charles Valla Hôpital Beaujon, Clichy, France BSG Postgraduate Course Birmingham](https://reader035.vdocument.in/reader035/viewer/2022062516/56649ddb5503460f94ad1e8a/html5/thumbnails/27.jpg)
Portal Vein Thrombosis Current guidelines in Beaujon
→ Permanent anticoagulation
No contraindication
Prophylaxis for PHT-related bleeding
Permanent prothrombotic disorder
![Page 28: Haematological and vascular complications affecting the liver Dominique-Charles Valla Hôpital Beaujon, Clichy, France BSG Postgraduate Course Birmingham](https://reader035.vdocument.in/reader035/viewer/2022062516/56649ddb5503460f94ad1e8a/html5/thumbnails/28.jpg)
Anticoagulation for BCS
Janssen et al, J Hepatol 2003. de Franchis, J Hepatol 2005.
• Anticoagulation recommended to all patients, in the absence of major contraindication.
• Previous bleeding from portal hypertension is not considered a major contraindication, provided appropriate prophylaxis for recurrent bleeding is initiated.
![Page 29: Haematological and vascular complications affecting the liver Dominique-Charles Valla Hôpital Beaujon, Clichy, France BSG Postgraduate Course Birmingham](https://reader035.vdocument.in/reader035/viewer/2022062516/56649ddb5503460f94ad1e8a/html5/thumbnails/29.jpg)
Conclusions
• Blood disorders are major causes of vascular liver diseases.
• Atypical myeloproliferative diseases most commonly implicated.
• Frequent combination of several causes.
• Permanent anticoagulation is generally recommended once prophylaxis for portal hypertensive bleeding has been instituted.